Personalized Medicine

A study involving 73 people with mild cognitive impairment or early dementia found that tailored treatment plans targeting nutritional deficiencies, infections and other factors led to significant cognitive improvements after nine months. Participants in the intervention group saw their overall cognitive scores rise by 13.7 points, while the control group declined by 4.5 points. The approach combines medical interventions with lifestyle changes like diet, exercise and cognitive training.

13 Mwezi wa nne, 2026 Imeripotiwa na AI

New research from Turkey shows that men with obesity tend to develop more abdominal fat and liver stress, while women exhibit higher inflammation and cholesterol levels. These findings, presented at the European Congress on Obesity in Istanbul, highlight sex-based differences that could inform personalized treatments. The study analyzed patients treated between 2024 and 2025.

Researchers led by the University of Cambridge report that an uncultured group of gut bacteria known as CAG-170 appears more abundant in healthy people and is less common in several chronic diseases, based on analysis of more than 11,000 gut metagenomes from 39 countries.

11 Mwezi wa pili, 2026 Imeripotiwa na AI Imethibitishwa ukweli

Researchers at Texas A&M University say they have developed a customizable “vessel-chip” that recreates the complex shapes of human blood vessels—including branches, aneurysm-like bulges and stenosis-like narrowings—so scientists can study how altered blood flow affects endothelial cells and evaluate potential treatments without relying on animal models.

Researchers in Dresden have discovered that the protein MCL1, known for helping cancer cells evade death, also regulates their energy production through the mTOR pathway. This dual role explains why drugs targeting MCL1 can fight tumors but sometimes harm the heart. The team has developed a dietary approach to mitigate this cardiotoxicity, paving the way for safer therapies.

5 Mwezi wa kwanza, 2026 Imeripotiwa na AI Imethibitishwa ukweli

A small randomized, double-blind trial suggests that MRI-based measures of brain structure may help predict which patients with major depressive disorder will show early symptom improvement after treatment with the traditional Chinese medicine Yueju Pill. In the four-day study, Yueju Pill and escitalopram were both associated with lower depression rating scores, but only Yueju Pill was linked to a rise in blood levels of brain-derived neurotrophic factor (BDNF).